Kelkheim, Germany

Sven Grueneberg



Average Co-Inventor Count = 7.6

ph-index = 2

Forward Citations = 16(Granted Patents)


Location History:

  • Frankfurt-am-Main, DE (2013)
  • Kelkheim, DE (2010 - 2014)

Company Filing History:


Years Active: 2010-2014

where 'Filed Patents' based on already Granted Patents

5 patents (USPTO):

Title: **Sven Grueneberg: Pioneering Innovations in Medical Chemistry**

Introduction

Sven Grueneberg, an accomplished inventor based in Kelkheim, Germany, has made significant contributions to the field of medical chemistry. With a portfolio of five patents, his work focuses on innovative compounds that aim to improve health outcomes by addressing critical medical challenges.

Latest Patents

Among his latest inventions are groundbreaking patents involving imidazole derivatives, specifically designed as TAFIa inhibitors. These compounds, represented by the formula (I), serve as inhibitors of the activated thrombin-activatable fibrinolysis inhibitor. They are particularly valuable in creating medications for the prevention and treatment of various diseases associated with thromboses, embolisms, hypercoagulability, and fibrotic conditions. In addition, Sven has developed CXCR2 inhibitors that are represented by a unique formula. These compounds, which may include pharmaceutically acceptable salts or prodrugs, have shown promise as inhibitors of chemokine receptors and are being investigated for the prevention and treatment of diseases mediated by chemokines.

Career Highlights

Sven Grueneberg has had an impressive career in the pharmaceutical industry, contributing his expertise to notable companies like Sanofi and Sanofi-Aventis Deutschland GmbH. His insights and innovations have paved the way for advancements in therapeutic compounds that hold the potential to revolutionize treatment options for patients.

Collaborations

Throughout his career, Sven has collaborated with distinguished colleagues, including Holger Heitsch and Stephanie Hachtel. These partnerships have fostered a rich environment for innovation and have enabled the sharing of knowledge and expertise in their field.

Conclusion

Sven Grueneberg stands out as a leading inventor in medical chemistry, particularly in the realm of innovative therapeutic compounds. With his impactful patents and dedication to improving patient care, he continues to contribute to the landscape of modern medicine. Through his work, he exemplifies the spirit of innovation that drives the industry forward.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…